Pulse Biosciences Inc

NASDAQ:PLSEUnited States

Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.

Contact Information

Headquarters

3957 Point Eden WayHAYWARD, CA, United States 94545-3720

Phone

510-906-4600

Fax

302-655-5049

Executives

Executive Chairman of the Board

Robert Duggan

President, Chief Executive Officer, Director

Burke Barrett

Chief Technology Officer, Director

Darrin Uecker

Chief Commercial Officer

Kevin Danahy

Chief Strategy Officer

Mitchell Levinson